Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solifenacin and mirabegron combination therapy study in overactive bladder
2012-005735-91Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Jul 2013
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of solifenacin and mirabegron in overactive bladder (OAB) (5 arms), sponsored by Astellas Pharma. Primary endpoint: Change from baseline in mean number of incontinence episodes per 24 hours at end of treatment. Started Jul 2013; status: completed.
02
Drugs
solifenacinmirabegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2012-005735-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005735-91.